LH

Business Context and Reporting Period

Company: Laboratory Corporation of America Holdings (LabCorp)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2008
Business Overview: LabCorp is the second-largest independent clinical laboratory company in the United States. It operates a national network of 36 primary laboratories and over 1,600 patient service centers, providing routine and specialty testing services (including oncology, HIV, and genetics) to physicians, hospitals, and managed care organizations. The company employs over 28,000 people and processes more than 440,000 patient specimens daily.

Key Financial Metrics (Year Ended Dec 31, 2008)

Margins: Gross margin was 41.6% in 2008 (down from 41.6% in 2007, though cost of sales as a % of sales increased to 58.4%). Operating margin was 18.7%.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 10.7% to $4.5 billion, driven by volume growth in managed care, the consolidation of the Ontario, Canada joint venture (effective Jan 1, 2008), and a shift toward higher-priced genomic and esoteric tests.
• Profitability: Net earnings decreased 2.6% to $464.5 million despite revenue growth, primarily due to increased bad debt expense, restructuring charges, and higher interest costs.
• Bad Debt Expense: Increased significantly to 6.2% of net sales (from 4.8% in 2007), including a $45.0 million increase in the provision for doubtful accounts in Q2 2008 due to economic conditions and higher patient deductibles.
• Restructuring: Recorded net restructuring charges of $32.4 million in 2008 (vs. $50.6 million in 2007) related to workforce reductions and facility closures.
• Debt: Interest expense rose 27.2% to $72.0 million due to borrowings under a Term Loan Facility and Revolving Credit Facility established in late 2007.

Guidance, Outlook, Risks, and Unusual Items

Management Commentary & Outlook

• Strategy: Focus remains on scientific differentiation (personalized medicine/companion diagnostics), managed care relationships, and customer service.
• UnitedHealthcare Contract: The company is the exclusive national laboratory for UnitedHealthcare. It expects total transition cost reimbursements to be approximately $125.6 million over the contract life.
• Pension Costs: Due to the 2008 stock market decline, projected pension expense is expected to increase from $19.5 million in 2008 to $34.2 million in 2009.
• Capital Expenditures: Expected to be approximately $130.0 million in 2009.

Risks and Contingencies

• Reimbursement Pressure: Continued pressure from Medicare, Medicaid, and private payers to reduce costs and utilization. A $7.5 million revenue adjustment was recorded in Q4 2008 for historic Medicare overpayments.
• Regulatory Environment: Significant risks related to fraud and abuse laws (False Claims Act), HIPAA compliance, and CLIA regulations. The company faces ongoing government inquiries and qui tam suits.
• Joint Venture Put Option: The Ontario joint venture minority interest holders have a put option to sell their units to LabCorp. The contractual value of this put exceeds the current minority interest by $98.8 million.
• Lehman Brothers: Lehman Brothers holds a $28.0 million commitment in LabCorp's revolving facility; the company does not expect Lehman to fulfill future borrowing requests.

Investor Verification Checklist

• Bad Debt Trends: Verify the sustainability of the 6.2% bad debt ratio and the impact of high-deductible health plans on collections.
• UnitedHealthcare Contract Economics: Assess the long-term profitability of the exclusive contract and the amortization of transition costs.
• Pension Liability: Monitor the projected increase in pension expense for 2009 and potential cash contributions required ($54.8 million planned).
• Debt Covenants: Confirm continued compliance with leverage (2.5:1) and interest coverage (5.0:1) ratios given the increased debt load.
• Regulatory Exposure: Review the status of the Medicare overpayment resolution and any new government investigations or qui tam filings.